Competitive Technologies (OTCMKTS:CTTC) vs. TransMedics Group (NASDAQ:TMDX) Head-To-Head Contrast

TransMedics Group (NASDAQ:TMDX) and Competitive Technologies (OTCMKTS:CTTC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.

Earnings & Valuation

This table compares TransMedics Group and Competitive Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$566.35 million	7.81	$35.46 million	$2.47	52.37
Competitive Technologies	N/A	N/A	N/A	N/A	N/A

TransMedics Group has higher revenue and earnings than Competitive Technologies.

Analyst Recommendations

This is a summary of current ratings and target prices for TransMedics Group and Competitive Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0	4	6	0	2.60
Competitive Technologies	0	0	0	0	0.00

TransMedics Group currently has a consensus target price of $144.25, suggesting a potential upside of 11.52%. Given TransMedics Group’s stronger consensus rating and higher probable upside, equities research analysts plainly believe TransMedics Group is more favorable than Competitive Technologies.

Profitability

This table compares TransMedics Group and Competitive Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransMedics Group	16.20%	31.42%	10.55%
Competitive Technologies	N/A	N/A	N/A

Institutional & Insider Ownership

99.7% of TransMedics Group shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by company insiders. Comparatively, 17.5% of Competitive Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

TransMedics Group beats Competitive Technologies on 8 of the 9 factors compared between the two stocks.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.